197 related articles for article (PubMed ID: 34539641)
1. Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer.
Yu S; Li X; Zhang J; Wu S
Front Immunol; 2021; 12():709493. PubMed ID: 34539641
[TBL] [Abstract][Full Text] [Related]
2. Construction of an immune-related gene signature for prediction of prognosis in patients with cervical cancer.
Mei J; Xing Y; Lv J; Gu D; Pan J; Zhang Y; Liu J
Int Immunopharmacol; 2020 Nov; 88():106882. PubMed ID: 32799114
[TBL] [Abstract][Full Text] [Related]
3. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
[TBL] [Abstract][Full Text] [Related]
4. Identifying a cervical cancer survival signature based on mRNA expression and genome-wide copy number variations.
Li N; Yu K; Lin Z; Zeng D
Exp Biol Med (Maywood); 2022 Feb; 247(3):207-220. PubMed ID: 34674573
[TBL] [Abstract][Full Text] [Related]
5. Lymph node metastasis-related gene signature shows good performance in predicting prognosis and immune infiltration in cervical cancer.
Guo Y; Wang L; Xu Z; Li M; Wang W; Bai Y; Xu X; Li R; Zhao H
Front Oncol; 2023; 13():1190251. PubMed ID: 37427104
[TBL] [Abstract][Full Text] [Related]
6. Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations.
Liu W; Jiang Q; Sun C; Liu S; Zhao Z; Wu D
BMC Cancer; 2022 Feb; 22(1):192. PubMed ID: 35184747
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Molecule PLA2G2D Is a Potential Prognostic Biomarker Correlating With Immune Cell Infiltration and the Expression of Immune Checkpoint Genes in Cervical Squamous Cell Carcinoma.
Liu H; Xu R; Gao C; Zhu T; Liu L; Yang Y; Zeng H; Huang Y; Wang H
Front Oncol; 2021; 11():755668. PubMed ID: 34733790
[TBL] [Abstract][Full Text] [Related]
8. Multi-Omics Analysis Showed the Clinical Value of Gene Signatures of C1QC
Li X; Zhang Q; Chen G; Luo D
Front Immunol; 2021; 12():694801. PubMed ID: 34295336
[TBL] [Abstract][Full Text] [Related]
9. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel six-gene signature with potential prognostic and therapeutic value in cervical cancer.
Qu X; Shi Z; Guo J; Guo C; Qiu J; Hua K
Cancer Med; 2021 Oct; 10(19):6881-6896. PubMed ID: 34498424
[TBL] [Abstract][Full Text] [Related]
11. Construction of an immune infiltration landscape based on immune-related genes in cervical cancer.
Yang Y; Wang N; Shi X; Wang Y; Yang C; Fan J; Jia X
Comput Biol Med; 2022 Jul; 146():105638. PubMed ID: 35605489
[TBL] [Abstract][Full Text] [Related]
12. Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma.
Zuo Z; Xiong J; Zeng C; Jiang Y; Xiong K; Tao H; Guo Y
Front Mol Biosci; 2021; 8():625470. PubMed ID: 33748188
[No Abstract] [Full Text] [Related]
13. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
14. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
15. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
Liao Y; He D; Wen F
Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of an immune prognostic signature in colorectal cancer.
Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy.
Yao S; Zhao L; Chen S; Wang H; Gao Y; Shao NY; Dai M; Cai H
Front Immunol; 2023; 14():1135657. PubMed ID: 36969161
[TBL] [Abstract][Full Text] [Related]
18. Identification of an immune-based mRNA-lncRNA signature for overall survival in cervical squamous cell carcinoma.
Mao Y; Chen R; Xia M; Guo P; Zeng F; Huang J; He M
Future Oncol; 2021 Jun; 17(18):2365-2380. PubMed ID: 33724869
[TBL] [Abstract][Full Text] [Related]
19. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
20. Tumor purity as a prognosis and immunotherapy relevant feature in cervical cancer.
Deng Y; Song Z; Huang L; Guo Z; Tong B; Sun M; Zhao J; Zhang H; Zhang Z; Li G
Aging (Albany NY); 2021 Nov; 13(22):24768-24785. PubMed ID: 34844217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
